Effects of prostaglandin F2α (PGF2α) on cell-death pathways in the bovine corpus luteum (CL)

Background Prostaglandin F2α (PGF2α) may differentially affect viability of luteal cells by inducing either proliferation or cell death (via apoptosis or necroptosis). The diverse effects of PGF2α may depend on its local vs. systemic actions. In our study, we determined changes in expression of gene...

Full description

Saved in:
Bibliographic Details
Published in:BMC veterinary research 2019-11, Vol.15 (1), p.416-416, Article 416
Main Authors: Jonczyk, Agnieszka Walentyna, Piotrowska-Tomala, Katarzyna Karolina, Skarzynski, Dariusz Jan
Format: Article
Language:English
Subjects:
Apoptosis
B-cell lymphoma
Bax protein
Bovine CL
Caspase
caspases
Cattle
Cell death
Cell proliferation
cell viability
Corpus luteum
cows
estrous cycle
Estrus cycle
Gene expression
gene expression regulation
genes
Immunohistochemistry
Kinases
Localization
luteal cells
luteolysis
Lymphocytes B
Lymphoma
MAP kinase
messenger RNA
Necroptosis
Ovariectomy
polymerase chain reaction
Prostaglandin F2α
prostaglandins
Protein kinase
protein kinases
Proteins
RIPKs
Viability
Western blotting
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Prostaglandin F2α (PGF2α) may differentially affect viability of luteal cells by inducing either proliferation or cell death (via apoptosis or necroptosis). The diverse effects of PGF2α may depend on its local vs. systemic actions. In our study, we determined changes in expression of genes related to: (i) apoptosis: caspase (CASP) 3, CASP8, BCL2 associated X (BAX), B-cell lymphoma 2 (BCL2) and (ii) necroptosis: receptor-interacting protein kinase (RIPK) 1, RIPK3, cylindromatosis (CYLD), and mixed lineage kinase domain-like (MLKL) in the early and mid-stage corpus luteum (CL) that accompany local (intra-CL) vs. systemic (i.m.) analogue of PGF2α (aPGF2α) actions. Cows at day 4 (n = 24) or day 10 (n = 24) of the estrous cycle were treated by injections as follows: (1) systemic saline, (2) systemic aPGF2α (25 mg; Dinoprost), (3) local saline, (4) local aPGF2α (2.5 mg; Dinoprost). After 4 h, CLs were collected by ovariectomy. Expression levels of mRNA and protein were investigated by RT-q PCR, Western blotting and immunohistochemistry, respectively. Results We found that local and systemic administration of aPGF2α in the early-stage CL resulted in decreased expression of CASP3 (P 
ISSN:1746-6148
1746-6148
DOI:10.1186/s12917-019-2167-3